# A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

> **NCT06205290** · PHASE3 · WITHDRAWN · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company**

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **BIOLOGICAL:** Liso-cel
- **DRUG:** Idelalisib
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06205290
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-16
- **Primary completion:** 2031-10-13
- **Final completion:** 2031-10-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205290, "A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06205290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*